The Hedge Fund Next Century Growth Investors Llc Trimmed its Position in Axogen Inc (NASDAQ:AXGN) by $11.31 Million

May 17, 2018 - By Michael Day

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

According to 2018Q1 Securities and Exchange form the Next Century Growth Investors Llc reduced its holdings in Axogen Inc (NASDAQ:AXGN) by 47.07%. By selling 314,239 shares Next Century Growth Investors Llc made the stock Popped Up with 43.24%. The health care company at the end of 2018Q1 was priced at $12.90M. It’s down from 667,642 at the end of the previous reported quarter. Now it had 353,403 shares held by the institutional investor . For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Next Century Growth Investors Llc is a Minnesota-based institutional investor with more than $3.86 billion AUM in March, 2014. Taken from Next Century Growth Investors latest Adv, the fund reported to have 10 full and part-time employees. Among which 6 performing investment advisory and research functions. The institutional investor had between 26-100 clients.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Total analysts of 7 have positions in AxoGen (NASDAQ:AXGN) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 21, 2017 according to StockzIntelligence Inc AxoGen has 11 analyst reports. On Wednesday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”. On Monday, January 8 Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) rating. Cantor Fitzgerald has “Buy” rating and $37.0 target. On Tuesday, November 21 the firm earned “Buy” rating by Wedbush. On Friday, March 2 the stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Buy” rating by Lake Street. On Tuesday, November 21 Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) rating. Leerink Swann has “Outperform” rating and $30 target. The stock rating was maintained by JMP Securities with “Market Outperform” on Thursday, March 1. On Tuesday, May 1 the rating was maintained by Cantor Fitzgerald with “Overweight”. On Tuesday, May 1 the rating was maintained by JMP Securities with “Market Outperform”.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The firm is valued at $1.66 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Last it reported negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: